Skip to main content
Download PDF

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

  • Poster presentation
  • Open access
  • Published:

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy

Journal for ImmunoTherapy of Cancer volume 3, Article number: P53 (2015) Cite this article

Background

Strategies that enhance the function of T cells are critical for immunotherapy.

Methods

Here we described for the first time a non-viral mediated approach to reprogram primary human T cells by disruption of PD-1.

Results

We showed that the gene knockout of PD-1 by electroporation of plasmids encoding sgRNA and Cas9 was technically feasible. The disruption of PD-1 resulted in significant reduction of PD-1 expression but didn't affect the viability of primary human T cells. Cellular immune response of the gene modified T cells was characterized by up-regulated IFN-γ production and enhanced cytotoxicity.

Conclusions

These results suggest that we have established an approach for efficient checkpoint inhibitor disruption, providing a new strategy for targeting checkpoint inhibitors to improve the efficacy of T cell based adoptive therapies.

figure 1
figure 2
figure 3

References

  1. Topalian SL, Hodi S, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012, 366: 2443-2454.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Pen JJ, Keersmaecker BD, Heirman C, Corthals J, Liechtenstein T, Escors D, et al: Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther. 2014, 21 (3): 262-271.

    Article  PubMed  CAS  Google Scholar 

  3. Lloyd A, Vickery ON, Laugel B: Beyond the antigen receptor: editing the genome of T cells for cancer adoptive cellular therapies. Front Immunol. 2013, 4: 221-

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Li W, Teng F, Li T, Zhou Q: Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat Biotechnol. 2013, 31 (8): 684-686.

    Article  PubMed  CAS  Google Scholar 

  5. Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, et al: Generation of gene- modified mice via Cas9/RNA-mediated gene targeting. Cell Res. 2013, 23: 720-723.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, et al: Generation of gene-modified Cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell. 2014, 156 (4): 1-8.

    Article  Google Scholar 

  7. Shen B, Zhang W, Zhang J, Zhou J, Wang J, Chen L, et al: Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. 2014, 11 (4): 399-402.

    Article  PubMed  CAS  Google Scholar 

  8. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 2014, 366 (26): 2443-2454.

    Article  Google Scholar 

  9. Iwamura K, Kato T, Miyahara Y, Naota H, Mineno J, Ikeda H, et al: siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T cell effector functions. Gene Therapy. 2012, 19 (10): 959-966.

    Article  PubMed  CAS  Google Scholar 

  10. Chicaybam L, Sodre AL, Curzio BA, Bonamino MH: An efficient low cost method for gene transfer to T lymphocytes. PLOS One. 2013, 8: e60298-

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank the entire Huang Lab and Liu Lab for their support and advice. This work was funded by grants from the National Natural Science Foundation of China (Grant No. 81172281, 81000980, 81220108023, 81172094).

Author information

Authors and Affiliations

  1. The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China

    Shu Su & Baorui Liu

  2. The Comprehensive Cancer Center of Drum-Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China

    Zhengyun Zou

Authors
  1. Shu Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baorui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhengyun Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Su, S., Liu, B. & Zou, Z. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy. j. immunotherapy cancer 3 (Suppl 2), P53 (2015). https://doi.org/10.1186/2051-1426-3-S2-P53

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/2051-1426-3-S2-P53

Keywords